Sevelamer 400 mg Tablets | Brand: Rexaver 400
Chronic Kidney Disease (CKD) is a growing global health concern, and with its progression, disturbances in mineral metabolism—especially hyperphosphatemia—become increasingly common. Managing elevated serum phosphorus levels is critical to reduce long-term complications such as vascular calcification, secondary hyperparathyroidism, and cardiovascular morbidity.
One of the most widely prescribed non-calcium-based phosphate binders for this purpose is Sevelamer. This article aims to educate pharmacists about Sevelamer, with a specific focus on Sevelamer 400 Tablets, marketed under the brand Rexaver 400, to support safe dispensing and informed pharmaceutical practice.
Understanding Sevelamer: The Molecule
Sevelamer is a non-absorbed, polymeric phosphate binder primarily indicated for the control of serum phosphorus levels in patients with chronic kidney disease, particularly those on hemodialysis or peritoneal dialysis.
Unlike calcium-based phosphate binders, Sevelamer does not contain calcium or aluminum, making it a preferred choice in patients at risk of hypercalcemia or soft tissue calcification.
Mechanism of Action
Sevelamer works locally in the gastrointestinal tract. It binds dietary phosphate through ionic and hydrogen bonding, forming an insoluble complex that is excreted via feces. Since Sevelamer is not systemically absorbed, its action remains confined to the gut, reducing the risk of systemic toxicity.
Sevelamer 400 Tablets: Dosage Strength Overview
Sevelamer 400 mg Tablets are commonly prescribed as an initial or titration dose, allowing flexibility in phosphate control based on individual patient needs and serum phosphorus levels.
Brand Highlight: Rexaver 400
- Generic Name: Sevelamer
- Strength: 400 mg
- Dosage Form: Oral Tablets
- Brand: Rexaver 400
Rexaver 400 provides a reliable and consistent option for phosphate management in CKD patients when used as per physician guidance.
Clinical Significance in CKD Management
Hyperphosphatemia strongly increases morbidity and mortality in patients with chronic kidney disease. Effective phosphate control using agents like Sevelamer helps in:
- Reducing serum phosphorus levels
- Lowering calcium-phosphorus product
- Minimizing vascular and soft tissue calcification
- Supporting better long-term cardiovascular outcomes
Additionally, Sevelamer may modestly reduce LDL cholesterol levels, benefiting CKD patients with cardiovascular risk factors.
Role of Pharmacists in Safe Dispensing
Pharmacists play a crucial role in optimizing therapy outcomes for patients prescribed Sevelamer 400 Tablets.
Key Counseling Points
- Administration with meals: Sevelamer must be taken with food to effectively bind dietary phosphate.
- Tablet swallowing: Tablets should be swallowed whole and not crushed unless advised.
- Drug interactions: Sevelamer can reduce the absorption of certain medications (e.g., ciprofloxacin, levothyroxine). Maintain adequate time gaps between Sevelamer and other interacting medications as per prescribing information.
- Adherence: Regular intake as prescribed is essential for effective phosphate control.
Safety Profile and Common Adverse Effects
Sevelamer does not undergo systemic absorption, which contributes to its favorable safety profile. However, pharmacists should be aware of common gastrointestinal side effects, including:
- Nausea
- Vomiting
- Constipation
- Abdominal discomfort
Patients with a history of bowel obstruction or severe gastrointestinal motility disorders require special caution.
Storage and Handling
- Store Sevelamer 400 Tablets in a cool, dry place
- Protect from moisture
- Dispense in original packaging to maintain stability
Why Non-Calcium Phosphate Binders Matter
With increasing awareness about calcium overload and vascular calcification risks, non-calcium phosphate binders like Sevelamer are becoming a cornerstone of CKD mineral bone disorder (CKD-MBD) management. Pharmacists should remain updated on such therapeutic advancements to support nephrologists and improve patient outcomes.
Sevelamer 400 Tablets, such as Rexaver 400, represent an essential therapeutic option in the management of hyperphosphatemia in CKD patients. With its non-calcium, non-absorbed profile and proven efficacy, Sevelamer continues to be a preferred choice in modern nephrology practice.
By understanding the molecule, mechanism, dosing nuances, and counseling requirements, pharmacists can contribute significantly to safe, effective, and compliant patient care.
This article is for educational purposes only for pharmacists and the medical fraternity to support safe and informed medical practice. This content serves educational purposes only and should not guide treatment decisions in place of professional medical judgment.